• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

The CorMicA Trial: Medical therapy guided by invasive coronary function testing offers symptomatic improvement of angina for patients with nonobstructive coronary artery disease

byJalal EbrahimandAnees Daud
December 4, 2018
in Cardiology, Chronic Disease
Reading Time: 4 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this blinded, randomized controlled trial, medical therapy guided by invasive coronary function testing offered greater improvements in angina severity compared with standard medical therapy alone.

2. There were no differences in major adverse cardiac events after 6 months.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Coronary artery disease (CAD) and angina are two of the most common medical conditions in North America, and coronary angiography is regularly utilized in part to diagnose and manage obstructive coronary artery disease. However, about half of patients will not have any obstructive coronary artery disease found despite anginal symptoms. Invasive coronary function testing provides higher sensitivity in assessing for microvascular angina (MVA) and vasospastic angina (VSA). This study was the first randomized control trial to assess if invasive coronary function testing linked to stratified medical therapy can provide symptomatic improvement.

The British Health Foundation Coronary Microvascular Angina (BHF CorMicA) study found that use of results from invasive coronary function testing improved recognition of MVA and VSA, reduced symptoms of angina, lowered rates of diagnosis of noncardiac chest pain, and increased rates of anti-anginal therapy as well as secondary preventative therapies such as ace-inhibitors and statins. There were no serious adverse effects secondary to invasive coronary function testing and rates of major cardiovascular/cerebrovascular adverse effects were the same across groups. Although the randomized control trial methodology was a strength of this study, there were some limitations. Firstly, the sample size was small, with only 151 patients randomized across two groups. Secondly, there were several significant differences between the control and intervention group, including more history of stroke/transient ischemic attack (17.1% vs 9.3%), lower rates of definite angina (55.5% vs 73.3%), and lower rates of abnormal myocardial perfusion imaging (43.3% vs 60.7%). In addition, the follow up time was short at only six months. Finally, the primary outcome was patient reported and therefore subjective, and in light of the inability to blind participants/attending cardiologists, there may have been some bias affecting responses.

Click to read the study, published today in JACC

RELATED REPORTS

The preoperative combination of evolocumab and rosuvastatin may not reduce major adverse cardiovascular events

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

Relevant Reading: Prevalence of Coronary Microvascular Dysfunction Among Patients With Chest Pain and Nonobstructive Coronary Artery Disease

In-Depth [randomized controlled trial]: This was a small, randomized, parallel group, sham-controlled trial with blinded outcome assessment. Inclusion criteria included adult patients referred for elective invasive coronary angiography at two large regional hospitals in the West of Scotland with definite/probable angina based on the Rose angina questionnaire. Exclusion criteria included noncardiac indication for angiography, inability to give informed consent, and obstructive coronary artery disease (CAD) (defined as at least 50% diameter stenosis or fractional flow reserve (FFR) < 0.80. There were 391 patients recruited between November 2016 and November 2017, of whom 151 had nonobstructive coronary artery disease and were randomized. The primary outcome was angina severity using the Seattle Angina Questionnaire summary score (SAQSS) score (scale 0 – 100). Secondary outcomes included health status using the EQ-5D-5L score, a widely used standardized instrument for measuring quality of life (scale -0.59 – 1.00), as well as diagnostic utility (frequency, certainty, and change in diagnosis, missed diagnoses), and clinical utility (impact on management). Outcomes were measured at 6 months. Safety was also assessed based on rate of major adverse cardiac and cerebrovascular events (MACE) including cardiovascular death, nonfatal myocardial infarction, hospitalization for heart failure, nonfatal stroke/transient ischemic attack, and resuscitated cardiac arrest.

All patients had invasive coronary function testing (invasive diagnostic procedures, or IDP) of fractional flow reserve (FFR), coronary flow reserve (CFR), and index of microcirculatory resistance (IMR). This was performed on a single major coronary artery to limit time added to the procedure (left anterior descending artery used unless technical factors precluded this). Patients were randomly assigned 1:1 to either the intervention group (medical therapy stratified according to IDP by attending cardiologist) or the control group (IDP performed but results not disclosed). In the intervention group, IDP results were used to classify patients as either having microvascular angina (MVA), vasospastic angina (VSA), both, or none. This classification was linked to guideline-based treatment for these patients. Attending cardiologists were provided with IDP results as well as information on guideline based management. Letters were also sent to general practitioners of patients in the intervention group with advice on tailoring and optimizing treatment in line with IDP results.

There were 148 patients (98%) who completed the primary outcome assessment (SAQ) at six months. There was greater reduction in angina severity in the intervention group (SAQSS improvement 14.4 vs 3.1, for treatment effect of -11.68 units [95% CI, -4.99 to -18.37, p=0.001]). Change in quality of life score was also higher in the treatment group (0.02 vs -0.07, treatment effect 0.10 [95% CI 0.01-0.18, p=0.024]). In terms of diagnostic utility, frequency of diagnosis of angina due to coronary artery function was 88.0% in the intervention group compared with 46.1% of the control group. Frequency of diagnosis of noncardiac chest pain was lower in the intervention group (16.0% vs 64.5%). In terms of clinical utility, physicians were more likely to include anti-anginal therapy for the intervention group (87.8% vs 48.7%). Secondary preventative therapies (including ace-inhibitors/statins) were also more commonly prescribed at 6 months in the intervention group (58.7% vs 36.8% for ace-inhibitors, 88.0% vs 53.9% for statins). No serious adverse events occurred secondary to the IDP, and rates of MACE were equivalent (2.6% vs 2.6%).

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anginaCoronary artery disease
Previous Post

Quick Take: Multicenter Trial of a Combination Probiotic for Children with Gastroenteritis

Next Post

Quick Take: Risk of Suicide After Cancer Diagnosis in England

RelatedReports

Heart attack treatment collage: an engraved heart with a shaded patch of damaged wall beside a dish of two white tablets
Cardiology

The preoperative combination of evolocumab and rosuvastatin may not reduce major adverse cardiovascular events

January 12, 2026
Blood pressure collage: a large artery cross-section ring, a tipped salt cellar spilling crystals and a plain wristwatch
Cardiology

Patients with coronary artery disease have sustained elevation in blood pressure following exercise

February 28, 2025
Cardiology

Optical coherence tomography-guided angioplasty reduces adverse events compared to angiography guidance

October 1, 2024
#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics
StudyGraphics

#VisualAbstract Edoxaban Monotherapy has Lower Risks for Atrial Fibrillation and Stable Coronary Artery Disease than Dual Antithrombotics

September 10, 2024
Next Post

Quick Take: Risk of Suicide After Cancer Diagnosis in England

Proton pump inhibitor co-therapy reduces gastrointestinal bleeding risk of oral anticoagulants

Liraglutide significantly reduces risk for major cardiac events in elderly patients with diabetes

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In online experiment, AI disagreement increased perceived laziness and uncertainty toward an LLM-simulated doctor
  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.